The Oncotype DX® Breast Cancer Assay, a multigene assay, stratifies breast cancer patients into groups that are at low, intermediate or high risk for distant recurrence and guides decision making for adjuvant chemotherapy. At the European Cancer Congress (ECC) 2015, André Robidoux, MD, FRCSC, of Centre Hospitalier de l’Université de Montréal, Montreal, Canada, explains the factors that were associated with the implementation of the Oncotype DX assay in different healthcare systems.
This content is supported by Genomic Health, Inc.
European Medical Journal
Advertisement
Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews